Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(E/Z)-Teriflunomide (Aubagio), a orally-available Pyrimidine Synthesis Inhibitor, is used to treat relapsing multiple sclerosis.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
25 mg | 在庫あり | ¥ 11,500 | |||
50 mg | 在庫あり | ¥ 13,000 | |||
100 mg | 在庫あり | ¥ 17,000 | |||
200 mg | 在庫あり | ¥ 22,500 |
説明 | (E/Z)-Teriflunomide (Aubagio), a orally-available Pyrimidine Synthesis Inhibitor, is used to treat relapsing multiple sclerosis. |
In vitro | In animal models of demyelinating diseases, Teriflunomide has demonstrated efficacy. For instance, in the black rat model of autoimmune encephalomyelitis, Teriflunomide has shown both preventive and therapeutic effects; similarly, in female Lewis rat models of Experimental Autoimmune Encephalomyelitis (EAE), it has been effective in ameliorating symptoms and reducing disease exacerbation. |
In vivo | Teriflunomide acts as a dihydroorotate dehydrogenase inhibitor, thereby inhibiting the de novo synthesis of pyrimidine in rapidly proliferating cells. By suppressing highly proliferative T and B lymphocytes, Teriflunomide effectively reduces the inflammatory response to self-antigens. |
別名 | Aubagio, HMR-1726, Flucyamide, A77 1726 |
分子量 | 270.21 |
分子式 | C12H9F3N2O2 |
CAS No. | 108605-62-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.25 mg/mL (23.13 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(E/Z)-Teriflunomide 108605-62-5 Metabolism Dehydrogenase Teriflunomide HMR1726 Aubagio HMR-1726 Flucyamide A77 1726 HMR 1726 Inhibitor inhibitor inhibit